Compare AbbVie Inc (ABBV) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs PepsiCo, Inc. — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while PepsiCo, Inc. trades at $142.95 (market cap $198.15B). The key difference: AbbVie Inc is far larger — about 2.3× PepsiCo, Inc.'s market cap, and PepsiCo, Inc. pays the higher dividend (4.08%). Which is the better fit depends on your goals.
| ABBV | PEP | |
|---|---|---|
Market Cap | $449.91B | $198.15B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $170.44 |
52-Week Low | $184.85 | $133.81 |
Enterprise Value | $513.38B | $240.05B |
Dividend Yield | 2.72% | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
PepsiCo (PEP) trades at $142.50, down 0.55% on the day, with a bullish technical signal despite bearish moving averages. The company maintains strong fundamentals with $93.93B revenue and consistent earnings beats, though net income margin declined to 8.77% in 2025. Recent news highlights price adjustments for snacks after consumer pushback on high prices, while analysts expect in-line Q1 2026 results.
PEP offers stable investment appeal with 34% analyst buy ratings and $161.73 consensus target, representing 13% upside. Risks include pricing sensitivity in North America and competitive pressures, but strong cash flow generation and dividend payments provide shareholder value support. The stock presents a balanced opportunity for income-focused investors seeking consumer staples exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
